22 / 24
Designing a continuumof care in MPC
=
2
nd
-line MM-398 + 5-FU/LV provides a break from neurotoxicity, paving the
way for subsequent 3
rd
-line treatment
=
Prior exposure to irinotecan (with 1
st
-line FOLFIRINOX) could increase the
potential for resistance to 2
nd
-line MM-398
1
st
line
2
nd
line
3
rd
line
Nab-paclitaxel
+ gemcitabine
MM-398+
5-FU/LV
FOLFOX/OFF
Oettle & Lehmann, Lancet 2016;387:507-8